摘要
目的 :研究可溶性细胞间黏附分子 1(solubleintercellularadhesionmolecule 1,sICAM 1)在活动期Graves眼病(Gravesopthalmopathy ,GO)患者治疗前后外周血中的表达 ,探讨sICAM 1在Graves眼病中的作用。方法 :4 2例活动期Graves眼病患者根据伴有或不伴有甲亢分为两组。同时设 2 0正常人为对照组。抽取所有患者激素治疗前后的血液 ,用Elisa方法检测血清中sICAM 1的浓度同正常健康人做对比。结果 :GO患者血清中的sICAM 1浓度显著高于对照组 ,伴甲亢者比不伴甲亢者血清中的sICAM 1浓度高 ,二者同对照组比较差异有显著意义。激素治疗后比治疗前显著降低 ,差异有显著意义 ;但与对照组相比差异无显著性。结论 :sICAM 1参与了Graves眼病的发生 ,其血清浓度同Graves眼病的活动性有关。检测患者血清中的sICAM 1浓度对评估Graves眼病的活动性有一定的临床意义。
Objective:To study the expression of solube intercellular adhesion molecule-1(sICAM-1)in the peripheral blood in patients with Graves ophthalmopathy(GO)and evaluate the effect of sICAM-1 on the occurrence and development of Graves ophthalmopathy.Methods:Fourty-two patients with active GO were divided into two groups on the bases of with or without hyperthyroidism.Group 1 included 25 patients with hyperthyroidism and group 2 included 17 patienis without hyperthyroidism.Twenty healthy volunteers was as control group.Elisa method was used to measure the level of serum sICAM-1 in all patients and control volunteers before and after glucocorticoid therapy.Results:The level of serum sICAM-l in all active patients was significantly higher than that of the control group.The level of serum sICAM-1 in group 1 was higher than in group 2.The level of serum sICAM-1 both groups before therapy was higher than after therapy.However.there was no significant difference after corticoid therapy compared with control group.Conclusions:The level of serum sICAM-1 is related to activity of Graves ophthalmopathy.sICAM-1 may participate in the occurrence and development of Graves ophthalmopathy.Assaying the concentration of serum sICAM-1 is helpful to evaluate the activity of this disease.
出处
《眼科》
CAS
2003年第1期53-55,共3页
Ophthalmology in China
